Becton Dickinson: Pharmaceutical Systems & Core Medical Consumables as Durable Growth Anchors!

Becton, Dickinson and Company (BD) reported its fourth-quarter and full-year fiscal 2025 results with several notable highlights and challenges, providing insights into its financial performance and future strategy. On the positive side, BD’s fourth-quarter revenue increased to $5.9 billion, a 7% year-over-year increase, and a 3.9% organic growth. For the full year, BD achieved a record revenue of $21.8 billion, marking a 7.7% increase, with a 2.9% organic growth. This growth was driven by the company’s New BD structure, particularly in segments like Medical Essentials, Connected Care, and BioPharma Systems. BD’s adjusted diluted EPS for the fourth quarter was $3.96, contributing to a record full-year EPS of $14.40, reflecting a 9.6% growth. Shareholder return was also highlighted by a $1 billion share buyback and a 54th consecutive year of dividend increases.